ReviewFrontline gastroenterology2020
Antibiotics and probiotics in inflammatory bowel disease: when to use them?
Review in Frontline gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Is the microbiome the answer to inflammatory bowel disease: systematic review.Langenbeck's archives of surgery · 2025Pooled it
- Can Mindfulness-Based Interventions Be Used to Treat PTSD-derived GI Disruptions in Black Women? A Review of Current Literature.Journal of racial and ethnic health disparities · 2026Review
- Probiotic drug interactions in ulcerative colitis: a microbiota and metabolite perspective.Frontiers in microbiology · 2026Review
- The gut microbiota predicts and time-restricted feeding delays experimental colitis.Gut microbes · 2025Article
- Longitudinal Monitoring of Inflammatory Bowel Disease in Mice Using Endoscopic Optical Coherence Tomography.Inflammatory bowel diseases · 2025Article
- Prevalence of Plasmid-Mediated Quinolone Resistance Genes inHealth science reports · 2024Article
- Drug Interaction-Informed Approaches to Inflammatory Bowel Disease Management.Pharmaceutics · 2024Review
- Targeting the Intestinal Microbiota: A Novel Direction in the Treatment of Inflammatory Bowel Disease.Biomedicines · 2024Review
- Dubosiella newyorkensis modulates immune tolerance in colitis via the L-lysine-activated AhR-IDO1-Kyn pathway.Nature communications · 2024Article
- Article
- Amelioration of acetic acid-induced ulcerative colitis in rats by cetirizine and loratadine via regulation of the PI3K/Akt/Nrf2 signalling pathway and pro-inflammatory cytokine release.Iranian journal of basic medical sciences · 2024Article
- Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives.World journal of gastroenterology · 2023Review
- Microbiota as key factors in inflammatory bowel disease.Frontiers in microbiology · 2023Review
- Evaluation of microbial and vancomycin treatments in ulcerative colitis in murine models.PloS one · 2023Article
- Mechanisms of mucosal healing: treating inflammatory bowel disease without immunosuppression?Nature reviews. Gastroenterology & hepatology · 2022Review
- Clinical Trials of Probiotics in Patients With Irritable Bowel Syndrome: Some Points to Consider.Journal of neurogastroenterology and motility · 2022Review
- An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis.Journal of clinical medicine · 2022Review
- Role of the gut microbiome in chronic diseases: a narrative review.European journal of clinical nutrition · 2022Review
- Successful Manipulation of the Gut Microbiome to Treat Spontaneous and Induced Murine Models of Colitis.Gastro hep advances · 2022Article
- Evaluation of Microbiome Alterations Following Consumption of BIOHM, a Novel Probiotic.Current issues in molecular biology · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotics and probiotics are often used as adjunctive therapy in inflammatory bowel disease. However, data are limited and randomised controlled trials are too inconsistent to provide generalised recommendations for their use in all patients with ulcerative colitis or Crohn's disease. Antibiotics are best used in the management of infectious complications and fistulas in Crohn's disease and, perhaps, in reducing the intensity of inflammation in luminal disease. Ciprofloxacin, metronidazole and rifaximin have been most widely used and studied. On the other hand, there appears to be a limited role for antibiotics in ulcerative colitis (UC). Probiotics are most effective in pouchitis, and may have a role in the initial therapy and maintenance of remission in mild UC; the probiotic cocktail VSL#3 has been the most widely studied. There is scant evidence of efficacy for probiotics in Crohn's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.